Thanks for posting. There are some posters here (like you) who...

Thanks for posting. There are some posters here (like you) who are well researched and the more knowledge you impart the higher quality these threads will be for everyone.

I’d add that GW Pharma hit a US$3 billion MC prior to generating one dollar of revenue from Epidiolex. Then revenue kicked off, scaled up quickly and Jazz acquired them for US$7.4 billion. This is not an isolated example in biotech stocks and it’s why we’re invested.

I think we all appreciate the clinical risk/reward but the probability of one indication becoming a drug is statistically higher with 5 independent trials and soon to be six. And OSA does appear to be advancing in the right direction.